Breast cancer (BC) is now the most common cancer in the world, and the disease is the leading cause of cancer death among women globally. BC is a heterogeneous disease with considerable genetic and clinical heterogeneity. BC is commonly classified based on aggressiveness, morphology, expression of immunohistochemical markers and, more recently, genomically, features that are associated with different treatment responses and prognoses. Currently, the origin of cancer stem cells, heterogeneity of cancer cells, cancer metastasis mechanisms and drug resistance are the most pressing issues that need to be addressed.
Fig. 1. Association between differentiation states of the mammary gland hierarchy and intrinsic breast cancer subtypes. (Yeo SK, et al., 2017)
Alfa Cytology's basic research on BC can help researchers better understand the mechanism, pathogenesis, diagnosis and treatment of BC, and reveal the origin of cancer cells, somatic mutations, epigenetic changes and tumor microenvironment.
Pathological testing refers to methods used to examine pathological changes in organs, tissues or cells of the body. To explore the physiological and biochemical changes in breast tumor tissues or cells, pathological detection methods can be used to examine the changes, explore the causes, mechanisms and development processes of the changes, and make pathological diagnosis.
Cells are the basic unit of structure and function of organisms and play an important role in the metabolic life activities of the body. Therefore, using a variety of precision instruments, combined with specific detection reagents, data sets compiled from multiple cell analysis studies allow researchers to better understand, predict, and ultimately influence the factors behind cell health, proliferation, function, and death.
The microbiota of BC patients differs from that of healthy people, suggesting that certain bacteria may be linked to the development of cancer and differential responses to treatment. Our services can help you explore the role of the human microbiome in BC development, its ability to modulate inflammation, immunity, and metabolism, and the impact that gut and local microbes may have on BC.
Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC basic research services and help in the treatment and diagnosis of BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.
Reference